Enzyme replacement therapy )

PreclinicalSmall molecule

Enzyme replacement therapy ) is one of 22 small molecule programs targeting Fabry Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fabry DiseaseActive, not recruiting

Fabry DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Fabry Disease

#DrugCompanyPhaseTrials

Fabrazyme (agalsidase Beta)

Sanofi

Approved

4 2

Active Comparator

Moderna

Phase 3

1 3

Venglustat

Sanofi

Phase 3

1 4

Agalsidase

Sanofi

Approved

8 5

Farxiga

AstraZeneca

Phase 2

1 6

Recombinant Alpha-Galactosidase a

AAssistance Publique - Hôpitaux de Paris

Approved

1 7

Replagal

Takeda

Phase 3

11 8

Galafold

AAmicus Therapeutics

Phase 3

3 9

Agalsidase Alfa

Takeda

Phase 3

6 10

Migalastat Hcl

AAmicus Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fabry Disease1 trial

Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease

Completed·UUniversity Hospital, Rouen·N/A·NCT02956954·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enzyme replacement therapy ). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enzyme replacement therapy ) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enzyme replacement therapy ). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Rouen

Enzyme replacement therapy )

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fabry Disease1 trial

References

Drug Info

Quick Facts

Related News